[A18-80] Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 16.05.2019
Project no.:
A18-80
Commission:
Commission awarded on 19.11.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
High-risk non-metastatic castration-resistant prostate cancer
Both positive and negative effects regarding side effects; added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-46 | Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A19-34 | Enzalutamide (prostate cancer) - Addendum to Commission A18-80 | Commission completed |
| A13-33 | Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A14-48 | Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A14-06 | Addendum to Commission A13-33 (enzalutamide) | Commission completed |
| A21-77 | Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-05-16 A G-BA decision was published.